Compare Becton Dickinson and Co (BDX) vs 8x8 Inc (EGHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs 8x8 Inc — how do they compare? Becton Dickinson and Co trades at $149.95 (market cap $41.51B), while 8x8 Inc trades at $2.17 (market cap $309.09M). The key difference: Becton Dickinson and Co is far larger — about 134.3× 8x8 Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| BDX | EGHT | |
|---|---|---|
Market Cap | $41.51B | $309.09M |
Sector | Health | Technology |
52-Week High | $185.39 | $2.76 |
52-Week Low | $135.49 | $1.59 |
Enterprise Value | $57.97B | $586.76M |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
EGHT trades at $2.22, up 8.29% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent product innovations in AI routing and workforce management demonstrate growth potential, though high P/E ratio of 218 and negative net income require careful valuation assessment.
EGHT presents a turnaround story with improving earnings momentum and AI-driven product expansion, but faces significant execution risks amid high valuation multiples. The stock's technical strength contrasts with fundamental challenges, requiring balanced risk-reward evaluation for investors seeking growth opportunities in communications technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
